Amgen News - LARVOL Sigma

«1 2...53 54 55 56 575859 60 61 62 63...858 859 »

|||||||||| Prolia (denosumab) / Amgen
Journal, Adverse events, Adverse drug reaction: Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS). (Pubmed Central) - Jun 25, 2024
Attention should also be paid to newly discovered ADRs, such as immobile, menopausal symptoms, etc., to avoid more serious consequences. Cohort studies, more detailed and comprehensive case information, and long-term clinical investigations are needed to confirm these results and to further understand the safety profile of Denosumab (Prolia).

||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
New P2 trial:  An Adaptive Design Study of MTX228 (clinicaltrials.gov) -  Jun 25, 2024
P2, N=24, Not yet recruiting,  Sponsor: University of Alberta

||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New P3 trial:  ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) -  Jun 25, 2024
P3, N=300, Not yet recruiting,  Sponsor: AstraZeneca

||||||||||  Repatha (evolocumab) / Amgen, Astellas
Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation (clinicaltrials.gov) -  Jun 25, 2024
P1, N=32, Completed,  Sponsor: Duke University
Cohort studies, more detailed and comprehensive case information, and long-term clinical investigations are needed to confirm these results and to further understand the safety profile of Denosumab (Prolia). Recruiting --> Completed | N=10 --> 32 | Trial completion date: Jun 2025 --> Oct 2023 | Trial primary completion date: Jun 2025 --> Sep 2023

||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial primary completion date:  TPO-Mimetic Use in Children for Hematopoietic Failure (clinicaltrials.gov) -  Jun 24, 2024
P1, N=15, Active, not recruiting,  Sponsor: Anjali Sharathkumar
Recruiting --> Completed | N=10 --> 32 | Trial completion date: Jun 2025 --> Oct 2023 | Trial primary completion date: Jun 2025 --> Sep 2023 Trial primary completion date: Jun 2024 --> Jan 2024

||||||||||  ivabradine / Generic mfg.
Trial completion date, Trial primary completion date:  IRISS: Ivabradine for Heart Rate Control In Septic Shock (clinicaltrials.gov) -  Jun 24, 2024
P3, N=429, Recruiting,  Sponsor: Assistance Publique - H
Trial primary completion date: Jun 2024 --> Jan 2024 Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Jan 2023 --> Sep 2024

|||||||||| Ibrance (palbociclib) / Pfizer
Journal: Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. (Pubmed Central) - Jun 24, 2024
In premenopausal women, who received tamoxifen plus OFS as ET, the addition of palbociclib to ET results in a favorable iDFS. The safety profile seems favorable and in contrast to chemotherapy palbociclib does not impact OF throughout the treatment period.

|||||||||| Repatha (evolocumab) / Amgen, Astellas
Preclinical, Journal: Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling. (Pubmed Central) - Jun 24, 2024
The safety profile seems favorable and in contrast to chemotherapy palbociclib does not impact OF throughout the treatment period. This study suggests that elevated PCSK9 causes atrial structural remodeling by enhancement of M1 macrophages polarization in atria, and evolocumab can effectively protects CIA rats from AF.

|||||||||| Rituxan (rituximab) / Roche
Journal: Occlusive Vasculitis Following Intravitreal Rituximab Injection for Primary Vitreoretinal Lymphoma. (Pubmed Central) - Jun 24, 2024
Occlusive vasculitis is a rarely reported but potential complication of intravitreal rituximab therapy in patients who have been previously treated with the agent and may have delayed onset. A low threshold for fluorescein angiography as a diagnostic test for post-injection vision loss and prompt treatment with topical and/or oral steroids should be considered.

|||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Real-world evidence, BRCA Biomarker, Real-world, Metastases: Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis. (Pubmed Central) - Jun 24, 2024
Tailoring of subsequent treatment strategy seems to be essential for achieving long-term benefit. Further studies are required, as the prognosis after CDK4/6i progression remains dismal, especially in cases affecting the central nervous system.

|||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Journal: Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury. (Pubmed Central) - Jun 24, 2024
Treatment with romosozumab did not lead to any significant improvement in bone mineral at the distal femur or proximal tibia. These findings provide promising results for romosozumab treatment to improve bone mineral and reduce fracture risk at the hip, but not the knee, in women with chronic SCI.

|||||||||| Prolia (denosumab) / Amgen
Journal: Response of Recurrent Aggressive Aneurysmal Bone Cyst of Distal Tibia to Denosumab Treatment. (Pubmed Central) - Jun 24, 2024
Further, follow-up and monitoring revealed the effectiveness of the local control and long-term treatment. This case report highlights the ability of denosumab to manage recurrent aggressive ABCs after surgical or sclerotherapy failure.

||||||||||  Repatha (evolocumab) / Amgen, Astellas
Enrollment change, Trial completion date, Trial primary completion date, Real-world evidence:  AMUNDSEN: Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI (clinicaltrials.gov) -  Jun 24, 2024
P4, N=2166, Recruiting,  Sponsor: Assistance Publique - H
This case report highlights the ability of denosumab to manage recurrent aggressive ABCs after surgical or sclerotherapy failure. N=1666 --> 2166 | Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2025

||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P4 trial:  Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study (clinicaltrials.gov) -  Jun 23, 2024
P4, N=63, Not yet recruiting,  Sponsor: Tuen Mun Hospital

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Enrollment change, Trial primary completion date:  Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia (clinicaltrials.gov) -  Jun 23, 2024
P2, N=33, Active, not recruiting,  Sponsor: Masonic Cancer Center, University of Minnesota
N=1666 --> 2166 | Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2025 Recruiting --> Active, not recruiting | N=20 --> 33 | Trial primary completion date: Dec 2025 --> Jun 2024

|||||||||| Imdelltra (tarlatamab-dlle) / Amgen
DLL3 Expression In Early () - Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_86;
A trend for improved survival in patients with no DLL3 expression was observed. Future studies on DLL3 might improve SCLC treatment SCLC.

|||||||||| Krazati (adagrasib) / BMS, Pozenveo (poziotinib) / Assertio, Lumakras (sotorasib) / Amgen
Pan-HER Inhibition Overcomes Feedback Adaptation Resistance to KRAS G12C Inhibition in KRAS G12C Mutant Non-Small Cell Lung Cancer (Grace Murray Hopper Auditorium, Yale West Campus Conference Center) - Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_66;
KRAS G12C inhibitors sotorasib and adagrasib are FDA approved for advanced/metastatic KRAS G12C-positive NSCLC, although the duration of benefit from these drugs is relatively modest and therapeutic resistance typically emerges relatively quickly to these drugs...We observed that in combination with KRAS G12C inhibitors pan-HER TKIs such as poziotinib yielded a synergistic effect compared to HER2 TKI treatment...The combination of pan-HER TKIs with KRAS G12C inhibitor suppressed tumor growth significantly as compared to KRAS G12C inhibitor alone with a tolerable toxicity profile in KRAS G12C mutant patients derived xenograft models. Collectively, our findings indicate that the adaptive feedback activation of HER family members, including not only EGFR but also HER2 and HER3, diminishes the efficacy of KRAS G12C inhibitors against KRAS G12C-positive NSCLC tumor cells, and that the combination of pan-HER TKIs with KRAS G12C inhibitors may be more effective than KRAS G12C inhibitors alone.

|||||||||| Identifying Resistant Mechanisms To Direct KRAS-Inhibitors (Grace Murray Hopper Auditorium, Yale West Campus Conference Center) - Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_28;
The identification of selective inhibitors of other oncogenic KRAS alleles, such as the noncovalent KRAS-G12D inhibitor, MRTX1133, and a pan-KRAS-inhibitor drug, BI3706674 is also a promising next step in the treatment of KRAS-dependent malignancies...We are currently performing in vitro and In vivo studies to understand the therapeutic efficacy of a TEAD inhibitor (VT107) in combination with KRASi (MRTX849 or MRTX1133) to either reverse or prevent resistance to the direct KRAS inhibitors. Successful completion of this research will help address the urgent need to understand ways to overcome resistance to KRAS inhibitors and increase their clinical efficacy.

|||||||||| Ibrance (palbociclib) / Pfizer, Spinraza (nusinersen) / Biogen, Ionis, Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
Retrospective data, Journal: Judicialization of high priced medications in Argentina: quali-quantitative study (Pubmed Central) - Jun 22, 2024
The rulings were mostly in favor of the plaintiff, and access times to the medication took a long time. The mass media anticipated the judicial processes.

||||||||||  AMG 193 / Amgen
Trial completion date, Trial primary completion date:  A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) -  Jun 21, 2024
P1, N=282, Recruiting,  Sponsor: Amgen
The mass media anticipated the judicial processes. Trial completion date: May 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Nov 2025

||||||||||  efavaleukin alfa (AMG 592) / Amgen
Trial completion date, Trial primary completion date:  Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) -  Jun 21, 2024
P2, N=320, Recruiting,  Sponsor: Amgen
Trial completion date: May 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Nov 2025 Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Feb 2025

||||||||||  Vectibix (panitumumab) / Amgen
Enrollment change, Trial withdrawal:  NCI-2021-03447: Pilot Study of 89-Zr Panitumumab in Pancreas Cancer (clinicaltrials.gov) -  Jun 21, 2024
P1, N=0, Withdrawn,  Sponsor: Stanford University
Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Feb 2025 N=14 --> 0 | Suspended --> Withdrawn

||||||||||  efavaleukin alfa (AMG 592) / Amgen
Trial completion date, Trial primary completion date:  Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) -  Jun 21, 2024
P2, N=140, Recruiting,  Sponsor: Amgen
N=14 --> 0 | Suspended --> Withdrawn Trial completion date: May 2028 --> Jan 2028 | Trial primary completion date: May 2028 --> Jan 2028

||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
Enrollment open:  DeLLphi-305: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (clinicaltrials.gov) -  Jun 21, 2024
P3, N=550, Recruiting,  Sponsor: Amgen
Trial completion date: May 2028 --> Jan 2028 | Trial primary completion date: May 2028 --> Jan 2028 Not yet recruiting --> Recruiting

|||||||||| ivabradine / Generic mfg.
Journal: Novel Use of Ivabradine for Persistent Sinus Tachycardia in a Patient on Extracorporeal Life Support With Right Ventricular Dysfunction. (Pubmed Central) - Jun 21, 2024
This case demonstrates the efficacy of ivabradine to reduce heart rate and avoid the use of beta-blockers for patients with RV dysfunction, which could be detrimental. Ivabradine was shown to lower the heart rate without altering hemodynamic parameters.

||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date:  Golden Gate Study: Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Jun 21, 2024
P3, N=287, Recruiting,  Sponsor: Amgen
Ivabradine was shown to lower the heart rate without altering hemodynamic parameters. Trial completion date: Sep 2031 --> Feb 2031 | Trial primary completion date: Dec 2026 --> May 2026

||||||||||  Stivarga (regorafenib) / Bayer
Enrollment open:  Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. (clinicaltrials.gov) -  Jun 21, 2024
P2, N=30, Recruiting,  Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2031 --> Feb 2031 | Trial primary completion date: Dec 2026 --> May 2026 Not yet recruiting --> Recruiting

||||||||||  Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Enrollment closed:  A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (clinicaltrials.gov) -  Jun 21, 2024
P2/3, N=130, Active, not recruiting,  Sponsor: Sun Pharmaceutical Industries Limited
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  Tavneos (avacopan) / Amgen
New P1 trial:  A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) (clinicaltrials.gov) -  Jun 21, 2024
P1, N=12, Not yet recruiting,  Sponsor: Amgen

|||||||||| Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Review, Journal, IO biomarker: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments. (Pubmed Central) - Jun 20, 2024
New KRASG12C inhibitors and several combination therapy strategies, including with immune checkpoint inhibitors, are being studied in clinical trials. The aim of this review is to explore the clinical impact of KRAS, and outline different treatment approaches, focusing on the novel treatment of KRASG12C-mutated NSCLC.

|||||||||| Prolia (denosumab) / Amgen
Retrospective data, Review, Journal, Real-world evidence, Real-world: Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis. (Pubmed Central) - Jun 20, 2024
The aim of this review is to explore the clinical impact of KRAS, and outline different treatment approaches, focusing on the novel treatment of KRASG12C-mutated NSCLC. This is the largest cohort study to show that denosumab treatment is associated with a reduced RR of incident T2D, as well as an associated reduced RR of all-cause mortality and microvascular complications, findings that may influence guideline development in the treatment of osteoporosis, particularly in patients who are at a high risk of T2D.

|||||||||| Prolia (denosumab) / Amgen
Journal, Surgery: Thoracic giant cell tumor after two total en bloc spondylectomies including one emergency surgery: A case report. (Pubmed Central) - Jun 20, 2024
This patient with acute paraplegia underwent TES twice, including once in an emergency, and achieved good therapeutic results. TES in emergency surgery is feasible and safe when conditions permit; however, it may increase the risk of tumor recurrence.

|||||||||| Tavneos (avacopan) / Amgen
Journal, Real-world evidence, Real-world: Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. (Pubmed Central) - Jun 20, 2024
After induction, the median (interquartile range [IQR]) time to start avacopan was 3.6 (2.1-7.7) weeks, and the median time to discontinue prednisone after starting avacopan was 5.6 (3.3-9.5) weeks...Of the patients, 20% stopped avacopan due to adverse events, with the most common being elevated serum aminotransferases (4.3%). A high rate of remission and an acceptable safety profile were observed with the use of avacopan in the treatment of AAV in this postmarketing analysis, including the populations excluded from the ADVOCATE trial.

|||||||||| Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Journal: A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sj (Pubmed Central) - Jun 20, 2024
After receiving two 300?mg injections of inebilizumab, not only the symptoms of NMOSD improved significantly, but also the symptoms of concurrent SS and pancytopenia. In the cases of AQP4-IgG seropositive NMOSD who have recurrent episodes and are comorbid with other autoimmune disorders, inebilizumab may be a good choice.

||||||||||  HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
New P3 trial:  A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) -  Jun 20, 2024
P3, N=429, Recruiting,  Sponsor: Genexine, Inc.

||||||||||  bemarituzumab (AMG 552) / Amgen
Trial completion, Enrollment change, Monotherapy:  A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov) -  Jun 19, 2024
P1, N=74, Completed,  Sponsor: Amgen
In the cases of AQP4-IgG seropositive NMOSD who have recurrent episodes and are comorbid with other autoimmune disorders, inebilizumab may be a good choice. Active, not recruiting --> Completed | N=180 --> 74

|||||||||| dazodalibep (HZN-4920) / Amgen
Clinical, P2 data, Journal: CD40 ligand antagonist dazodalibep in Sj (Pubmed Central) - Jun 19, 2024
P2
In summary, DAZ appears to be a potential new therapy for SjD and its efficacy implies an important role for the CD40/CD40 ligand pathway in its pathogenesis. ClinicalTrials.gov identifier: NCT04129164 .

|||||||||| azenosertib (ZN-c3) / Zentalis Pharma, Lumakras (sotorasib) / Amgen
Journal: Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. (Pubmed Central) - Jun 19, 2024
Notably, the combined inhibition of KRAS-G12C and WEE1 consistently suppresses tumor growth. Our results suggest targeting WEE1 as a promising therapeutic strategy for KRAS-mutated NSCLC with TP53 mutations.

|||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: Bispecific T cell engager therapy for refractory rheumatoid arthritis. (Pubmed Central) - Jun 19, 2024
Here we treated six patients with multidrug-resistant rheumatoid arthritis (RA) with the CD19xCD3 BiTE blinatumomab under compassionate use...Together, these data suggest the feasibility and potential for BiTEs to treat RA. This approach warrants further exploration on other B-cell-mediated autoimmune diseases.

|||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Neuroprotective Effect of Filgrastim against Rotenone induced Parkinson's disease in Rats (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4775;
This approach warrants further exploration on other B-cell-mediated autoimmune diseases. Outcomes of the current study suggest neuroprotective potential of filgrastim and its ability to correct movement disability and thus could prove to be useful candidate molecule in the management of motor disorders.

|||||||||| ivabradine / Generic mfg.
Hyperpolarization-activated cyclic nucleotide-gated channel inhibitor, Ivabradine, attenuates brain mitochondrial oxidative stress without reducing cognitive impairment in Dox-induced chemobrain (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2668;
Iva treatment showed a reduction in brain mitochondrial ROS, with no improvement in mitochondrial membrane potential changes and swelling in Dox-induced chemobrain. Iva did not improve cognitive function and hippocampal-synaptic plasticity in Dox-treated rats.

|||||||||| Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen, Rituxan (rituximab) / Roche
Journal: Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders. (Pubmed Central) - Jun 19, 2024
Moreover, it demonstrates a partial effect in preventing optic nerve atrophy. Thus, it stands as an effective method to reduce the disability rates and improve the daily living ability of patients with NMOSD.

|||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Case report: Sequential inotuzumab, blinatumomab, and chemotherapy with concurrent donor lymphocyte infusions induce complete remission in relapsed pre-B acute lymphoblastic leukemia. (Pubmed Central) - Jun 19, 2024
This case highlights the feasibility and potential synergistic efficacy of a Blina/DLI regimen and supports the hypothesis that T-cell engagers could enhance the DLI effect. Furthermore, the co-administration of InO, Blina, DLI, and cytoreductive chemotherapy was proven to be feasible without severe adverse events.

|||||||||| Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Therapeutic Decisions in Glomerular Diseases: Updating the Algorithms (Room 6A, Convention Center) - Jun 19, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_225;
Learning Pathway(s). Glomerular Diseases .

|||||||||| bortezomib / Generic mfg., Ibrance (palbociclib) / Pfizer, MG132 / Jilin University, Dorothy M. Davis Heart and Lung Research Institute
Journal: Novel drug targets and molecular mechanisms for sarcopenia based on systems biology. (Pubmed Central) - Jun 19, 2024
Finally, validation experiments in muscle cell line (C2C12) revealed MG-132 and troglitazone as promising candidates for sarcopenia treatment. Our approach, based on systems biology and drug repositioning, provides insight into the molecular mechanisms of sarcopenia and offers potential new treatment options using existing drugs.

|||||||||| Review, Journal, Metastases: Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. (Pubmed Central) - Jun 19, 2024
This review highlights the efficacy of multikinase inhibitors and immune checkpoint inhibitors in monotherapy and combination therapy through the analysis of phase II, and III clinical trials, targeting the key molecular pathways involved in cellular signaling and immune response for the prospective treatment of advanced and unresectable HCC and discusses the upcoming combinations of immune checkpoint inhibitors-tyrosine kinase inhibitors and immune checkpoint inhibitors-vascular endothelial growth factor inhibitors. Finally, the hidden challenges with pharmacological therapy for HCC, feasible solutions for the future, and implications of possible presumptions to develop drugs for HCC treatment are reported.

|||||||||| Imlygic (talimogene laherparepvec) / Amgen
Review, Journal, Metastases: Intralesional and Infusional Updates for Metastatic Melanoma. (Pubmed Central) - Jun 19, 2024
In 2015, the Food and Drug Administration (FDA) approved the first oncolytic intralesional therapy, talimogene laherparepvec (T-VEC), for the treatment of advanced melanoma...While some of these treatments have less utility due to inferior outcomes as well as higher toxicity profiles, there are selective patient profiles for which these therapies carry a role. This review highlights intralesional and infusional therapies for the management of metastatic melanoma.

|||||||||| Imlygic (talimogene laherparepvec) / Amgen
Journal, Metastases: Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma. (Pubmed Central) - Jun 19, 2024
However, we did not find a significant difference in locoregional recurrence or OS. Future studies are needed to assess the sequence and timing of combining RT and TVEC to potentially enhance the immune response both locally and distantly.

|||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal, Stroma: Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy. (Pubmed Central) - Jun 19, 2024
Several clinical trials are evaluating the safety and efficacy of Tezepelumab in various inflammatory disorders. In this review, we will highlight major recent advances in understanding the functional role of TSLP, its involvement in Th2-related diseases, and its suitability as a target for biological therapies.

|||||||||| Vectibix (panitumumab) / Amgen
Journal: Trichomegaly Due to Panitumumab. (Pubmed Central) - Jun 19, 2024
In this review, we will highlight major recent advances in understanding the functional role of TSLP, its involvement in Th2-related diseases, and its suitability as a target for biological therapies. No abstract available



	Diseases Companies Products Productz Mechanisms of Action Sites